Drug Discovery is a multifaceted process involving the identification, development, and optimization of compounds to treat diseases effectively. At its core, drug discovery aims to address unmet medical needs by targeting specific biological pathways or molecular targets associated with diseases. This process typically begins with target identification, where researchers pinpoint key molecules or proteins involved in the disease process. Following target identification, screening methods such as high-throughput screening or virtual screening are employed to identify potential drug candidates from large compound libraries. Once promising compounds are identified, they undergo rigorous testing in preclinical studies to assess their safety, efficacy, and pharmacokinetic properties. Preclinical studies involve in vitro and in vivo experiments to evaluate the compound's therapeutic potential and potential adverse effects. Promising candidates then advance to clinical trials, where they are tested in human subjects to assess their safety and efficacy in treating the target disease. Clinical trials are conducted in multiple phases, each designed to gather specific data on the drug's safety and effectiveness. Phase I trials focus on determining the drug's safety profile and appropriate dosage levels in healthy volunteers, while Phase II and Phase III trials involve testing the drug's efficacy and safety in patients with the target disease.
Title : Improving health in over 40,000 patients: The impact of nanomedicine fighting antibiotic resistant infections
Thomas J Webster, Brown University, United States
Title : Renewed novel biotech ideas, with bioreactor bioengineering economic impact
Murray Moo Young, University of Waterloo, Canada
Title : Osmotic lysis–driven Extracellular Vesicle (EV) engineering
Limongi Tania, University of Turin, Italy
Title : Predicting wound closure and future segmentation masks in wound healing assays
Alfredo De Cillis, Univeristy of Salento, CNR Nanotec, Italy
Title : Scientist’s computational lawyer
Julia Sidorova, Instituto Carlos III de Salud (CIBER-EHD), Spain
Title : Evaluating cell compatibility and subcutaneous host response of silk fibroin–chitosan plug composites as potential resorbable implants
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico